Ex-FDA deputy director Wikler joins Rib-X
This article was originally published in Scrip
Dr Matthew Wikler, a former deputy director of the US FDA, has joined biopharmaceutical company Rib-X Pharmaceuticals as chief development officer. Dr Wikler will take up his new post, leading development of the company's skin infection product candidates, from 30 April. During his two years at the FDA, Dr Wikler served as deputy director of the division of anti-infective drug products. He most recently served as president and CEO of IASO Pharma.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.